Supplementary Figures 7 - 14, Tables 3 - 7 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

<p>PDF file - 310KB, Figure S7: Comparison of copy number ratios at the 1q21.2 (MCL1) locus and 1q23.3; Figure S8: IGV screenshots of the 1q23.3 amplified region (Figure 3) for both cohorts; Figure S9: Kaplan-Meier curves for the second 1q23.3 GISTIC peak, located around FCGR3B; Figure S10: Kaplan-Meier curves for the PBX1 GISTIC peak at 1q23.3 (peak 3); Figure S11: Venn diagram of patients with amplification (log2 > 0.9) of the three GISTIC peaks in the (a) Spanish, (b) DFCI and (c) TCGA cohorts; Figure S12: Boxplots visualizing the correlation of mRNA expression and copy number in the Spanish cohort for all genes in the 1q23.3 GISTIC peak 1; Figure S13: Boxplots visualizing the correlation of mRNA expression and copy number in the DFCI cohort for all genes in the 1q23.3 GISTIC peak 1; Figure S14: Panel (a) shows the correlation of copy number and Immunohistochemistry (IHC) staining of the PVRL4 gene in the Spanish cohort; Table S3: Associations of GISTIC peaks with overall survival after start of chemotherapy, adjusted for ECOG performance status and visceral disease (Spanish cohort); Table S4: Copy numbers in all bladder cancer cohorts at all three 1q23.3 GISTIC peaks. Numbers of patients in the TCGA cohort correspond to patients with clinical information; Table S5: Associations of ECOG PS, visceral disease, 1q23.3 amplification (peak 2, FCGR3B gene) and OS; Table S6: Associations of ECOG PS, visceral disease, 1q23.3 amplification (peak 3, PBX1 gene) and OS; Table S7: For the genes in 1q23.3, this table lists the correlations of copy number and mRNA expression and the correlations of overall survival and mRNA expression.</p>